Nakwon Kwak
서울대학교 내과 · 의학
Nakwon Kwak 교수의 연구실은 결핵 및 다제내성결핵(MDR-TB), 특히 <i>Mycobacterium abscessus</i> 폐결핵와 같은 난치성 뇌증균 감염의 치료 전략과 진단 기법 개선을 핵심으로 연구를 진행하고 있습니다. Xpert MTB/RIF와 같은 신속진단 기술의 임상적 정확도와 시행 시간 분석을 통해 진단 효율성을 높이고자 하며, 치료 성과 향상을 위한 신약제 사용 전략의 유효성도 평가하고 있습니다. 특히, 다국적 환자 데이터를 기반으로 한 메타분석과 임상 연구를 통해 실질적인 치료 지침을 제시하고자 합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Treatment of <i>Mycobacterium abscessus</i> pulmonary disease (MAB-PD), caused by <i>M. abscessus</i> subsp. <i>abscessus</i>, <i>M. abscessus</i> subsp. <i>massiliense</i> or <i>M. abscessus</i> subsp. <i>bolletii</i>, is challenging.We conducted an individual patient data meta-analysis based on studies reporting treatment outcomes for MAB-PD to clarify treatment outcomes for MAB-PD and the impact of each drug on treatment outcomes. Treatment success was defined as culture conversion for ≥12 mo
After South Korea raised its infectious disease alert to the highest level in response to coronavirus disease emergence, tuberculosis notification during the first 18 weeks of 2020 decreased significantly from the same period for each year during 2015-2019. Adequate measures to diagnose, control, and prevent tuberculosis need to be maintained.
The Xpert MTB/RIF assay was introduced for timely and accurate detection of tuberculosis (TB). The aim of this study was to determine the diagnostic accuracy and turnaround time (TAT) of Xpert MTB/RIF assay in clinical practice in South Korea. We retrospectively reviewed the medical records of patients in whom Xpert MTB/RIF assay using sputum were requested. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of pulmonary tuberculos
Treatment outcomes for MDR-TB improved at a tertiary referral centre in South Korea. The improvement was associated with more frequent use of later-generation fluoroquinolones and linezolid.
This study was registered to the ClinicalTrials.gov (Identifier: NCT01616745 / registration date: June 12, 2012). The protocol was retrospectively registered.
This study was performed at Seoul National University Hospital ( NCT01616745 ).
Clinical outcomes are different according to the size of cavities in patients with cavitary NTM-PD; thus, the measurement of the size of cavities could help in making clinical decisions.
Clofazimine demonstrated a relatively favorable efficacy in severe MAC-PD, regardless of the maintenance dose. This effect was more pronounced when administered for a duration exceeding 6 months.
ClinicalTrials.gov identifier: NCT03934034.
